Solomon Moshkevich Sells 3,000 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $140.48, for a total transaction of $421,440.00. Following the completion of the transaction, the insider now directly owns 141,782 shares in the company, valued at approximately $19,917,535.36. The trade was a 2.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, March 17th, Solomon Moshkevich sold 1,026 shares of Natera stock. The shares were sold at an average price of $146.04, for a total transaction of $149,837.04.
• On Wednesday, March 5th, Solomon Moshkevich sold 6,000 shares of Natera stock. The stock was sold at an average price of $143.29, for a total transaction of $859,740.00.
• On Wednesday, January 29th, Solomon Moshkevich sold 5,201 shares of Natera stock. The shares were sold at an average price of $165.87, for a total value of $862,689.87.
• On Wednesday, January 22nd, Solomon Moshkevich sold 24,861 shares of Natera stock. The stock was sold at an average price of $164.97, for a total value of $4,101,319.17.

Natera Price Performance

NTRA opened at $133.87 on Friday. The firm has a market cap of $18.10 billion, a PE ratio of -76.06 and a beta of 1.80. The stock has a 50-day moving average price of $156.81 and a 200-day moving average price of $151.40. Natera, Inc. has a 1 year low of $83.13 and a 1 year high of $183.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.01. The business had revenue of $476.10 million during the quarter, compared to analysts’ expectations of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. Sell-side analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Natera

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. LRI Investments LLC purchased a new position in shares of Natera in the fourth quarter worth $29,000. Blue Trust Inc. raised its position in Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after buying an additional 97 shares during the last quarter. Versant Capital Management Inc lifted its stake in Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 166 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in shares of Natera by 372.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock valued at $52,000 after acquiring an additional 261 shares during the last quarter. Finally, Principal Securities Inc. grew its stake in shares of Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after acquiring an additional 59 shares during the period. 99.90% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

NTRA has been the subject of a number of recent analyst reports. BTIG Research restated a “buy” rating on shares of Natera in a report on Friday, February 28th. JPMorgan Chase & Co. upped their price objective on shares of Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. Sanford C. Bernstein lifted their target price on shares of Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, January 10th. Piper Sandler increased their price target on shares of Natera from $200.00 to $205.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 4th. Finally, Robert W. Baird raised their price objective on shares of Natera from $183.00 to $188.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $178.12.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.